-
State hospital associations throughout the nation should be in receipt of a May 6, 2008, letter from U.S. Rep. Henry Waxman, chairman of the Committee on Oversight and Government Reform, asking what they are doing to prevent health care-associated infections (HAIs).
-
In the silence after the speakers had concluded the opening session recently in Orlando of the annual meeting of the Society for Healthcare Epidemiology of America (SHEA) as those with questions were moving to the microphones moderator Patrick J. Brennan, MD, acknowledged what many were thinking by noting that there was an "800-pound gorilla in the room."
-
As the field of infection prevention undergoes sweeping changes, the Society for Healthcare Epidemiology of America (SHEA) must reassess its role and redefine its mission, an epidemiologist said recently in Orlando at the group's annual meeting.
-
A fascinating, philosophical exchange among some of the nation's leading health care epidemiologists recently came down to the value of zero.
-
In this Issue: Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
-
Over the past several years, Japan has been the chief source of measles importation into the United States. A total of 63 cases of measles were imported to the United States from Japan during the past 22 years.
-
Comparison of Both Clinical Features and Mortality Risk Associated with Bacteremia due to Community-Acquired Methicillin-Resistant Staphylococcus aureus and Methicillin-Susceptible S. aureus. Clinical Infectious Diseases 2008;46:799-806.
-
For 2 years beginning in February, 2005, every patient admitted to the Royal Infirmary of Edinburgh with community-acquired pneumonia (CAP) had blood levels of C-reactive protein (CRP) measured at the time of admission and (if still in the hospital) 4 days later. A standardized set of clinical and laboratory data was also acquired for each patient, per hospital routine.
-
In this Issue: Pioglitazone and heart disease; ARBs manufacturers spend
millions to show the non-inferiority of their products compared to less
expensive, generic ACE inhibitors; some athletes turn to growth hormone
because it is difficult to detect; FDA Actions